Related Experiment Videos
Tat peptides inhibit neprilysin.
Abigail Daily1, Avindra Nath, Louis B Hersh
1Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky 40538-0509, USA.
Journal of Neurovirology
|August 1, 2006
Summary
Human immunodeficiency virus (HIV) Tat peptides inhibit neprilysin, an enzyme that degrades amyloid beta. This inhibition may explain amyloid accumulation in HIV-associated dementia.
Area of Science:
- Neuroscience
- Virology
- Biochemistry
Background:
- Dementia is common in aging HIV patients, with amyloid deposition observed even in younger individuals.
- HIV's Tat protein is neurotoxic and activates glial cells, contributing to neuropathogenesis.
- Tat protein and its peptides may dysregulate amyloid processing by inhibiting neprilysin.
Purpose of the Study:
- To investigate the effect of HIV Tat protein and its derived peptides on neprilysin activity.
- To determine the mechanism of neprilysin inhibition by Tat peptides.
Main Methods:
- Inhibition assays using homogeneous recombinant neprilysin.
- Testing of both Tat protein and Tat-derived peptides.
- Analysis of inhibition kinetics (competitive, reversible).
Main Results:
- Tat-derived peptides, but not the full Tat protein, competitively and reversibly inhibit neprilysin.
- Neprilysin slowly hydrolyzes both Tat peptides and Tat protein.
- Accumulation of Tat fragments may lead to sustained neprilysin inhibition.
Conclusions:
- HIV Tat peptides inhibit neprilysin, a key enzyme for amyloid beta clearance.
- This inhibition mechanism could contribute to amyloid deposition in HIV-associated neurocognitive disorders.
- Tat-derived fragments may prolong neprilysin inhibition, exacerbating amyloid accumulation.